SAB Biotherapeutics (SABS) Consolidated Net Income (2021 - 2026)

SAB Biotherapeutics has reported Consolidated Net Income for 6 years, with the latest figure at -$19.0 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income fell 76.39% year-over-year to -$19.0 million; the trailing twelve-month figure through Mar 2026 stood at -$56.0 million (down 45.8% YoY), and the FY2025 full-year result was -$47.8 million, down 13.87% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$19.0 million, down from -$15.1 million in the prior quarter.
• The five-year high for Consolidated Net Income was $985863.0 in Q1 2022, with the low at -$22.9 million in Q4 2023.
• Historically, Consolidated Net Income has averaged -$9.4 million across 5 years, with a median of -$7.8 million in 2022.
• Annual changes were most pronounced in 2023 — Consolidated Net Income sank 845.93% — and 2024, when it jumped 56.5%.
• SAB Biotherapeutics' Consolidated Net Income stood at -$7.8 million in 2022, then slumped by 191.21% to -$22.9 million in 2023, then surged by 56.5% to -$9.9 million in 2024, then slumped by 52.19% to -$15.1 million in 2025, then slipped by 25.64% to -$19.0 million in 2026.
• The last three Consolidated Net Income figures came in at -$19.0 million (Q1 2026), -$15.1 million (Q4 2025), and -$12.1 million (Q3 2025), per Business Quant data.